Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139054 | 0.92 | PDPK1 (0.62) | PDPK1POLBKMT2AMEN1 | |
| SCHEMBL656058 | 0.92 | PDPK1 (0.62) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL657707 | 0.87 | PDPK1 (0.56) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL2142907 | 0.86 | PDPK1 (0.63) | PDPK1KMT2AMEN1L3MBTL1 | |
| SCHEMBL658265 | 0.86 | PDPK1 (0.72) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL2142669 | 0.86 | PDPK1 (0.72) | PDPK1KMT2AMEN1L3MBTL1 | |
| SCHEMBL2141563 | 0.86 | PDPK1 (0.63) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL10256955 | 0.85 | POLB (0.72) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL657374 | 0.85 | KMT2A (0.72) | PDPK1POLBKMT2ACYP2C9CYP2C19 | |
| SCHEMBL657492 | 0.85 | PDPK1 (0.76) | PDPK1POLBKMT2ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258477-B1 | CATALYST AND MICHAEL ADDITION REACTION PROCESS | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8222177-B2 | Catalyst and reaction process | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258477-A1 | CATALYST AND REACTION PROCESS | Japan Science and Technology Agency (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | PDPK1 4324/4885POLB 859/4885KMT2A 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.